A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT06034002 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasms

Interventions

DRUG: INCA033989
DRUG: Ruxolitinib

Sponsor

Incyte Corporation